许多研究[1]均证实,慢性乙型肝炎病毒(Hepatitis B vi-rus,HBV)感染者的病毒载量与乙肝患者病死率及肝细胞癌的发生率显著相关。一项大型随机对照研究[2]显示,拉米夫定治疗可延缓进展性肝纤维化或肝硬化的临床进程,减少原发性肝癌的发生,延长患者生存期。提示我们抗病毒治疗是 Many studies [1] have confirmed that the viral load of patients with chronic hepatitis B (HBV) infection is significantly related to the mortality of patients with hepatitis B and the incidence of hepatocellular carcinoma. A large randomized controlled study [2] showed that lamivudine treatment can delay the progress of advanced liver fibrosis or cirrhosis, reduce the incidence of primary liver cancer and prolong the survival of patients. Prompted us for antiviral treatment is